Combined or sequential treatment of advanced melanoma?

Bożena Cybulska-Stopa¹, Tomasz Świtaj², Hanna Kosela-Paterczyk²

¹Clinical Oncology Clinic, Maria Skłodowska-Curie Institute – Oncology Center, Krakow Branch, Poland
²Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland

Melanoma is a malignant neoplasm with a very high rate of growth in the number of cases. In Poland, in the years 1980–2010, the number of cases of melanoma increased threefold. Although the incidence rates of melanoma are rising, the mortality rate due to melanoma is falling. In recent years, the treatment of patients with melanoma has changed to a great extent. Thanks to the development of molecular research, the presence of specific mutations in melanoma cells was discovered. The progress in understanding the molecular mechanisms occurring in this neoplastic cells and the interaction between the immune system cells and melanoma cells contributed to the development of new classes of drugs: immunotherapy and targeted therapy.

With the use of checkpoint inhibitors, long-term remission of the disease can be achieved, which has been confirmed in many clinical trials that have shown improvements in overall survival (OS) and progression free survival (PFS). However, the predominant problem is the low response rate to checkpoint inhibitors and the time between the initiation of therapy and the response to treatment. This is not the case with targeted therapies, where the response rate is high and the response time is very short. Therefore, a promising treatment strategy can be a combination of these two classes of drugs, so that one can try to achieve a quick and long-term response to the treatment. The paper discusses the current treatment options for melanoma patients in the spreading phase of the disease and analyzes the benefits of combined and sequential treatment.

**Key words:** melanoma, immunotherapy, targeted therapy, sequential treatment

**Introduction**

Melanoma is a malignant neoplasm with a very high rate of growth in the number of cases. In Poland, in the years 1980–2010, the number of cases of melanoma increased threefold [1, 2]. Although the incidence rates of melanoma are rising, the mortality rate due to melanoma is falling. Low grade melanoma has a very good prognosis and is usually completely curable with surgical methods, while 5-years survival rate reaches as much as 99%. However, melanomas with metastases to regional lymph nodes or distant metastases are characterized by much worse prognosis: 5-year survival rates are 63% and 20% respectively [3]. Despite significant progress, the prognosis of patients with melanoma in the spreading phase of the disease is still unsatisfactory and new treatment strategies are constantly being sought.

In recent years, the treatment of patients with melanoma has changed to a great extent. Thanks to the development of molecular research, the presence of specific mutations in melanoma cells was discovered. It is estimated that melanoma cells show *BRAF* V600 mutation in about 50% of patients with disseminated melanoma [4]. The progress in understanding the molecular mechanisms occurring in melanoma cells and the interaction between the immune system cells and melanoma cells contributed to the development of new classes of drugs: immunotherapy and targeted therapy. Immunotherapy is based on immune checkpoint inhibitors (ICIs), which inc-
The analysis of 12 clinical trials confirmed the potential long-survival rate (the percentage of 2-year OS was 28.5%) [11, 12].

demonstrated in some patients and an improvement in total dacarbazine) in the first-line therapy, long-term responses were the dose of 10 mg/kg of body weight (in combination with In 2011, in a study evaluating the efficacy of ipilimumab at than in the control group (median survival time: 6.4 months). – 10.1 months and in both cases it was significantly higher 10.0 months, of patients treated with ipilimumab and gp100 -11.9% [21].

In phase III KEYNOTE-006 study, with the participation of patients with advanced melanoma, who had not been previously taken part in systemic treatment. Patients were assigned to 3 groups of patients receiving pembrolizumab every 2 or 3 weeks or ipilimumab [21]. The median OS was 32.7 months in groups treated with pembrolizumab and 15.9 months in groups treated with ipilimumab. The median PFS was 8.4 and 3.4 months respectively [22, 23]. Objective responses were obtained in the group receiving pembrolizumab every 2 or 3 weeks in 33.7% and 32.9% of patients respectively, and in the group treated with ipilimumab in 11.9% [21].

Combination therapy using anti-CTLA-4 with anti-PD-1

The first attempts to combine CTLA-4 and PD-1 inhibitors were made in phase I, where the combination of nivolumab at a dose of 1 mg/kg of body weight with ipilimumab at a dose of 3 mg/kg of body weight was tested [24]. The basic study that evaluated the efficacy of combination therapy: nivolumab with ipilimumab was the phase III study CheckMate-067 [25]. The

**Immunotherapy**

**Anti-CTLA-4 or anti-PD-1 monotherapy**

**Ipilimumab**

Ipilimumab is a recombinant human monoclonal antibody, IgG1 subclass, with a half-life of 12–14 days, binding to the CTLA-4 (CD152) molecule [14]. By blocking CTLA-4, the anti-neoplastic immune response is activated. Three phase II studies – CA184-022, CA184-008 and CA184-007 [5–7] – using ipilimumab in monotherapy in patients with advanced melanoma showed a median survival rate of 8.6–11.0 months and a percentage of 1-year survival rate of 39–48%. Subsequent analyses showed a 2-year survival rate of 30% [8] and a 3-year survival rate of 25% at the dose of 10 mg/kg of body weight. [9]. However, there is no data available to indicate that this drug leads to permanent cures in melanoma patients. In 2010, the results of the phase III study (MDX010-20) using ipilimumab in patients with advanced melanoma were presented [10]. The median survival time of patients treated with ipilimumab was 10.0 months, of patients treated with ipilimumab and gp100 – 10.1 months and in both cases it was significantly higher than in the control group (median survival time: 6.4 months). In 2011, in a study evaluating the efficacy of ipilimumab at the dose of 10 mg/kg of body weight (in combination with dacarbazine) in the first-line therapy, long-term responses were demonstrated in some patients and an improvement in total survival rate (the percentage of 2-year OS was 28.5%) [11, 12]. The analysis of 12 clinical trials confirmed the potential long-
median OS was not obtained in the group receiving nivolumab with ipilimumab, in the group with nivolumab it was 36.9 months, and in the group with ipilimumab 19.9 months. The median PFS reached 11.5 months, 6.9 months and 2.9 months respectively, with objective responses of 57.6%, 43.7% and 19% respectively. It should be noted that the combination of nivolumab with ipilimumab gave better results in patients with low expression of PD-L1 in melanoma tissue (<5%). In case of high expression of PD-L1 in melanoma tissue, the treatment results for monotherapy with nivolumab and combined therapy with PFS and OS were similar [25]. Adverse events related to treatment in grade 3 and 4 have been reported:

- in the group receiving nivolumab with ipilimumab – in 185 (59%) out of 313 patients,
- in the group receiving nivolumab – in 70 (22%) out of 313 patients,
- in the group receiving ipilimumab – in 86 (28%) out of 311 patients [26, 27].

Another study that evaluated the association of anti-CTLA-4 with anti-PD-1 was the II/IV phase of CheckMate-511 study [28]. It compared 2 different doses of both drugs, i.e. nivolumab at a dose of 1 mg/kg of body weight with ipilimumab at a dose of 3 mg/kg of body weight (NIVO1+IPI3) and nivolumab at a dose of 3 mg/kg of body weight with ipilimumab at a dose of 1 mg/kg of body weight. (NIVO3+IPI1). Objective response to treatment was obtained in 45.6% of cases in the NIVO3+IPI1 group and 50.6% in the NIVO1+IPI3 group, and the percentage of complete remissions – (CR) was 15.0% and 13.5% respectively. The median OS was not obtained in any of the groups and the median PFS was 9.9 months in the NIVO3+IPI1 group and 8.9 months in the NIVO1+IPI3 group. Annual PFS was 47.2% and 46.4% respectively and annual OS was 79.7% and 81% respectively.

The association of pembrolizumab at a dose of 2 mg/kg of body weight with ipilimumab at a dose of 1 mg/kg of body weight at the phase Ib of KEYNOTE-029 study was also evaluated. The number of objective responses to treatment was 61%, including 15% of CR. In 27% of treated patients adverse effects were reported in grades 3 and 4 [29, 30].

**Targeted therapy**

**Monotherapy with BRAF or MEK inhibitors**

**Vemurafenib**

Vemurafenib is a low molecular weight BRAF serine threonine kinase inhibitor used in melanoma patients with mutations in the BRAF gene [31]. In phase III of the BRIM-3 study, vemurafenib and dacarbazine were compared in patients with advanced melanoma, who had not previously undergone systemic treatment, with the presence of mutations in the **BRAF V600E** gene [32]. The median OS in the group receiving vemurafenib was 13.6 months and in the group with dacarbazine – 9.7 months in the analysis before cross-over to vemurafenib (in the analysis after cross-over the median OS was 10.3 months). The median PFS was 6.9 and 1.6 months respectively [32, 33]. The 1-, 2-, 3- and 4-year survival rate constituted 56% and 46%, 30% and 24%, 21% and 19%, as well as 17% and 16%, respectively. In the group receiving vemurafenib, 48% of responses to treatment were reported, and in the group treated with dacarbazine – 5% [32].

**Dabrafenib**

Dabrafenib is a reversible BRAF V600 kinase inhibitor used in melanoma patients with mutations in the **BRAF** gene. In the BREAK-3 study, dabrafenib was compared with dacarbazine in patients with advanced melanoma with the present **BRAF V600E** mutation who had not received previous systemic treatment. Because of the planned cross-over to dabrafenib after disease progression, the primary endpoint was PFS, which in the group with dabrafenib was 5.1 months and in the group with dacarbazine – 2.7 months [34]. According to data presented at the ASCO conference in 2013, the median OS in the dabrafenib-treated group was 18.2 months and in the dacarbazine-treated group 15.6 months, while the number of responses to dabrafenib treatment was 59% [17].

**Encorafenib**

Encorafenib, like dabrafenib and vemurafenib, is an inhibitor of **BRAF V600** kinase. However, it differs from them by 10 times longer half-life of dissociation (>30 h). This probably results in higher antineoplastic activity and at the same time less activation of the MAPK pathway in healthy tissues, which is responsible for the development of adverse effects [37]. The combination of encorafenib with binimetinib compared to encorafenib or vemurafenib was evaluated in the COLUMBUS study [43, 44].

**Trametinib**

Trametinib is a selective, low-molecular, selective inhibitor of MEK1 and MEK2 kinase. Trametinib was evaluated in phase III of the METRIC study and compared with chemotherapy (dacarbazine or paclitaxel) in patients with advanced melanoma with **BRAF V600E/K** mutation [35]. In this study, the median PFS was 4.9 months for trametinib and 1.5 months for chemotherapy, and 1-, 2-, 5-year total survival for trametinib and chemotherapy was 60.9% and 49.6%, 32.0% and 29.4%, 13.3% and 17.0% respectively. In the vast majority of patients at the early stage of treatment, a cross-over (n = 70, 65%) to trametinib was used [36].

**Binimetinib**

Binimetinib, just as trametinib, is an oral, low-molecular, selective inhibitor of MEK1 and MEK2 kinase. Its efficacy was assessed in a phase III study with NEMO randomization, where it was compared with dacarbazine in patients with advanced melanoma with *NRAS* mutation. The median OS in the group receiving binimetinib was 11 months, and in the group receiving dacarbazine – 10.1 months. The median PFS was 2.8 and 1.5 months respectively, and the rate of responses was 15% and 7% respectively [38].
Therapy combined with BRAF and MEK inhibitors

Vemurafenib with cobimetinib

The efficacy of the combination of vemurafenib and cobimetinib was confirmed by phase III of coBRIM study [39]. It showed the advantage of combination of vemurafenib and cobimetinib over monotherapy with vemurafenib. The median OS and PFS for the combination was 22.3 and 12.3 months for the combination and 12.3 and 7.3 months for the vemurafenib respectively. Similarly, the number of objective responses for vemurafenib with combimetinib was 70% and 50% respectively. One of the advantages of using the combination in comparison with monotherapy with BRAF inhibitor was significantly lower number of skin complications.

Dabrafenib with trametinib

The combination of dabrafenib and trametinib was evaluated in two studies of the third phase of COMBI-d [40] and COMBI-v [41]. In the first one, dabrafenib with trametinib was compared to dabrafenib and in the second one to vemurafenib. The median OS in COMBI-d was 25.1 months for the combination and 18.7 months for the trametinib, the median PFS was 11 and 8.8 months respectively, while the number of objective responses to treatment ranged from 69% to 53%. In the COMBI-v study, the median OS for the combination was 25.6 months and for vemurafenib 18 months, while the median PFS was 11.4 and 7.3 months, respectively, and the number of responses to treatment was 64% and 51%. The updated 5-year follow-ups in COMBI-d and COMBI-v showed a 4-year PFS of 21% and a 5-year PFS of 19%. Four-year OS was 37% and five-year OS was 34%. Total remission was observed in 19% of patients with 5-year-old OS at 71% [42].

Encorafenib with binimetinib

The efficacy of the combination of encorafenib and binimetinib was evaluated in the COLUMBUS study [43, 44]. Encorafenib and binimetinib were compared with encorafenib or vemurafenib. The OS median for the combination was 33.6 months and 16.9 months for vemurafenib. The median PFS for encorafenib with binimetinib was 14.9 months, for encorafenib 9.6 months and for vemurafenib 7.3 months. However, the number of objective responses to treatment was 64%, 52% and 41% respectively.

Immunotherapy with targeted therapy

Combinations of immunotherapy and targeted therapy are currently being tested in many clinical trials. This treatment is used in patients with melanoma with the current mutation in the BRAF gene. This combination of therapies seems very promising. It enables a significant number of responses to be obtained in a short time using BRAFi-MEKi and a long-term maintenance of these responses during treatment with checkpoint inhibitors. Another justification for this management strategy is based on different mechanisms of action of individual therapies, which, due to their complementary action, may improve the effects of treatment [45].

The first combinations of targeted therapies with immunotherapy for melanoma referred to ipilimumab and vemurafenib. However, the study was discontinued due to significant hepatotoxicity of combined therapy [46]. Subsequent studies concerned the combination of ipilimumab or nivolumab or pembrolizumab with dabrafenib and trametinib [47]. The first results of treatment with pembrolizumab, dabrafenib and trametinib are promising, with PFS of 16 months and 59.8% response rates with a median response time of 18.7 months and acceptable treatment toxicity [47]. The study evaluating the toxicity of the combination of atezolizumab, vemurafenib and cobimetinib resulted in 71.8% objective responses and 39.3% with a median response duration of 17.4 months [48]. Currently, patients with advanced melanoma are undergoing a number of clinical trials to combine targeted therapy with immunotherapy, but most often these are phase I and phase II studies [49]. However, the results of treatment of patients with advanced melanoma are still yet to come, as they require confirmation in subsequent clinical trials.

Strategy of management of patients with advanced melanoma

At the present, the following therapies are registered for the treatment of patients with melanoma in inoperable grade III and grade IV:

**Combined treatment**

- patients with a present mutation in the **BRAF** gene:
  - dabrafenib with trametinib
  - encorafenib with binimetinib
  - vemurafenib with cobimetinib
  - nivolumab with ipilimumab
- patients with no mutation in the **BRAF** gene:
  - nivolumab with ipilimumab (currently not refundable in Poland).

**Monotherapy**

- patients with a mutation in the **BRAF** gene:
  - dabrafenib
  - trametinib
  - vemurafenib
  - nivolumab
  - pembrolizumab
  - ipilimumab
- patients with no mutation in the **BRAF** gene:
  - nivolumab
  - pembrolizumab
  - ipilimumab.

In the light of current studies, the use of targeted therapies as monotherapy may be justified only in case of significant complications during BRAFi-MEKi combination therapy [39–
However, if complications occur during combined therapy, the combination of BRAFi and MEKi with a different toxicity profile should be considered first. In the case of checkpoint inhibitors, the use of immunotherapy as a monotherapy is preferred in most patients due to its low toxicity. The combination of nivolumab and ipilimumab should be recommended especially in patients with asymptomatic CNS metastases [50–52]. However, the sequence of therapies, especially in patients with the present mutation in the \textit{BRAF} gene, remains a problem.

A very practical solution was proposed in the work by Schvartsman et al. [50]. He distinguished two prognostic groups among patients with melanoma in inoperable grade III and in grade IV: low and high risk (table I). Then, depending on the risk group and the presence or absence of metastases in the CNS, he presented 4 possible scenarios of management (fig. 1–4):

- low-risk patients without metastases in CNS;
- low-risk patients with metastases in CNS;
- high-risk patients without metastases in CNS;
- high-risk patients with metastases in CNS.

Such a division can be very useful in everyday medical practice. It seems that if the patient is in good general condition, the tumor mass is small and occurs in 1–2 locations and the LDH level is normal or slightly elevated, the best option is to start therapy with checkpoint inhibitors. Of course, attention should be paid to possible contraindications to immunotherapy and a discussion with the patient about other available therapeutic options.

In situations where the disease is rapidly progressing and a mutation is present in the \textit{BRAF} gene, BRAFi and MEKi are the therapies of choice (in some cases checkpoint inhibitors may also be considered). One can also optionally start treatment with BRAFi and MEKi (for a short period of time) to stop the neoplastic process and then move on to immunotherapy. However, new therapeutic options and drug combinations are being sought to achieve long-term survival in this group of patients.

**Table I.** Prognostic groups of patients according to Schvartsman et al. [50]

| Factor/group | Low-risk group | High-risk group |
|--------------|----------------|-----------------|
| Tumor mass size | <10 cm | ≥10 cm |
| Number of locations where metastases were found | <3 locations | ≥3 locations |
| LDH concentration value | Normal | ≥2 × upper limit of normal |
| Performance status | 0 or 1 | ≥2 |

**Low-risk patient without metastases in CNS**

- \textit{- anti-PD-1} (nivolumab or pembrolizumab)
- \textit{- nivolumab with ipilimumab}*

*preferred in patients with \textit{BRAF} mutation, high level of LDH or negative PD-L1, however, there is no management consensus

**Low-risk group**

- tumor mass size (total volume) <10 cm
- number of metastases locations <3 locations
- normal LDH level
- radioterapia + anty PD-1
- performance status 0 or 1

**Progression**

**BRAFi + MEKi**

- encorafenib + binimetinib or
- dabrafenib + trametinib or
- vemurafenib + cobimetinib

**BRAF−**

- no clear guidelines:
  - clinical study
  - ipilimumab (if anti-PD-1 monotherapy used earlier)
  - chemotherapy
  - radiotherapy + anti-PD-1
  - HD IL-2
  - T-VEC (if lesions in skin or subcutaneous tissue are present)
  - symptomatic treatment
Low-risk patient with metastases in CNS

- anti-PD-1 (nivolumab or pembrolizumab)
- stereotactic radiotherapy with anti-PD-1 (surgical excision should be considered in the case of large single lesions that cannot be treated with stereotactic radiotherapy or if treatment with steroids is necessary)
- anti-PD-1 (nivolumab or pembrolizumab)

Progression
(if progression only to CNS, stereotactic radiotherapy and continued immunotherapy should be considered)

BRAF+
- BRAFi + MEKi
  - encorafenib + binimetinib or
dabrafenib + trametinib or
  - vemurafenib + cobimetinib

BRAF–

No clear guidelines:
- clinical study
- ipilimumab (if anti-PD-1 monotherapy used earlier)
- chemotherapy
- symptomatic treatment

High-risk patient without metastases in CNS

- tumor mass size (total volume) ≥10 cm
- number of metastases locations ≥3 locations
- LDH level: 2 x upper limit of normal
- performance status ≥2

Progression
(patients with BRAF mutation)
- nivolumab with ipilimumab (preferred option)
or
- anti-PD-1 (nivolumab or pembrolizumab)

BRAF+
- BRAFi + MEKi
  - encorafenib + binimetinib or
dabrafenib + trametinib or
  - vemurafenib + cobimetinib

Progression
(patients should be monitored very carefully for the progression of the disease and if it occurs, immunotherapy should be started immediately)

BRAF–

Low-risk group
- tumor mass size (total volume) <10 cm
- number of metastases locations <3 locations
- normal LDH level
- performance status 0 or 1

High-risk group
- tumor mass size (total volume) ≥10 cm
- number of metastases locations ≥3 locations
- LDH level: 2 x upper limit of normal
- performance status ≥2
Summary
The emergence of new therapies has certainly improved the survival rates of melanoma patients. However, there is still a group of patients in whom the efficacy of the treatment is unsatisfactory and further research is needed to answer the question: “Why do these patients not respond to the treatment applied?” Other problems have also emerged in relation to the toxicity of new drugs and the sequence and duration of treatment, which require further research.

Conflicts of interest: Bożena Cybulska-Stopa: lectures, analyses, conferences sponsored by BMS, MSD, ROCH, Novartis, Pierre Fabre.

Bożena Cybulska-Stopa
Maria Skłodowska-Curie Institute – Oncology Center, Krakow Branch Clinical Oncology Clinic
ul. Garncarska 11
31-115 Kraków, Poland
e-mail: bcybulskastopa@vp.pl

Received and accepted: 21 Aug 2019

References
1. Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer et al. Cutaneous melanomas. Oncol Clin Pract. 2019; 15
2. Dziedzicka J, Wojciechowska U, Ołasek P. Nowotwory płucne w Polsce w 2015 roku. Cancer in Poland in 2015. Warszawa 2015.
3. Yu C, Liu X, Yang J et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front. Immunol. 2019; 10: 990.
4. Kakadiya S, Yarlagadda A, Aved R et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco. Targets Ther. 2018; 11: 7095–7107.
5. Wolchok JD, Neyns B, Lintett G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2009; 15: 5591–5596.
6. O’Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, placebo-controlled, phase II study. Ann. Oncol. 2010; 21: 1712–1717.
7. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2010; 16: 6254–6260.
8. Maio M, Lebbé C, Sileni VCh et al. Three-year survival rates for patients with advanced melanoma who received ipilimumab at 10 mg/kg in Phase II Trials. ESMO Congress 2009; poster 116.
9. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363: 711–723.
10. Carty L, Biggins S, Schadendorf D et al. Ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2011; 364: 2517–2526.
11. Świtaj T, Wysocki P, Wójcikiewicz W et al. Ipilimumab – progress in therapy of advanced melanoma. Onkologia w Praktyce Klinicznej. 2011; tom 7, nr 5, 231–245.
12. Schadendorf D, Hodi F, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J. Clin Oncol. 2015; 33: 1889–1894.
14. Wang C, Thudium KB, Han M et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicity in non-human primates. Cancer Immunol Res. 2014; 2: 846–856.
15. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372: 320–330.
16. Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16 (4): 375–384.
17. Nowe terapia w czerniakach. Biblioteka chirurga onkologa red. P. Rukowski Via-Medica, Gdańsk 2016.
18. Ascierto PA, Long GV, Robert C et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019; 5 (2): 187–194.
19. Larkin J, Minor D, D’Angelo S et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate037: a randomized, controlled, open-label phase 3 trial. J Clin Oncol. 2018; 36 (4): 383–390.
20. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dosecomparison cohort of a phase 1 trial. Lancet. 2014; 384: 1109–1117.
21. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521–2532.
22. Long GV, Schachter J, Ribas A et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) for 2-years in patients (pts) with ipilimumab (ipi)-naïve advanced melanoma in KEYNOTE-006. J Clin Oncol. 2018; 36: 9503–9503.
23. Robert C, Ribas A, Schachter J et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20: S1470-2045(19)30388-2.
24. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122–133.
25. Larkin J, Chiarion-Silieni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23–34.
26. Hodi F, Chiarion-Silieni V, Gonzalez R et al. LBA44 Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). Ann Oncol. 2018; 29: mdy424. 054.
27. Hodi F5, Chiarion-Silieni V, Gonzalez R et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2019; 18 (9): 1489–1492.
28. Lebbé C, Meyer N, Mortier L et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb IV checkMate 511 trial. J Clin Oncol. 2019; 37: S395–S391.
29. Long GV, Atkinson V, Celbon JS et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017; 18: 1202–1210.
30. Wolchok JD, Chiarion-Silieni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017; 377: 1345–1356.
31. Kozak K, Rutkowski P. Skuteczność i bezpieczeństwo wemurafenib zu w leczeniu chorych na nieresekcyjnego czerniaka skóry w świetle aktualnych wyników badania BRIM-3. Onkologa w Praktyce Klinicznej. 2014; tom 10, nr 4, 196–196.
32. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364 (26): 2507–2516.
33. Chapman PB, Robert C, Larkin J et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017; 28 (10): 2581–2587.
34. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358–365.
35. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367: 107–114.
36. Robert C, Flaherty K, Nathan P et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAFV600 E/K-mutant advanced or metastatic melanoma. Eur J Cancer. 2019; 109: 61–69.
37. Kozak K, Rutkowski P. Why do we need a new BRAF-MEK inhibitor combination in melanoma? Oncol Clin Pract. 2019; 15.
38. Dummer R, Schendendorf D, Ascierto PA et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18 (4): 435–445.
39. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371: 1867–1876.
40. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371: 1877–1888.
41. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372: 30–39.
42. Robert C, Grob JJ, Stroyakovskiy D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019; 380: 963–965.
43. Dummer R, Ascierto PA, Gogas HJ et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19 (5): 603–615.
44. Dummer R, Ascierto PA, Gogas HJ et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19 (10): 1315–1327.
45. Atkins M, Larkin J. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. JNCI J Natl Cancer Inst. 2016; 108 (6): djv414.
46. Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and cobimetinib. N Engl J Med. 2013; 368 (14): 1365–1366.
47. Ascierto PA, Ferrucci PF, Fisher R et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF mutant melanoma. Nature Medicine. 2019.
48. Sullivan RJ, Hamid O, Gonzalez R et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature Medicine. 2019.
49. Yu C, Liu X, Yang J et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front. Immunol. 2019; 10: 999.
50. Schwartzman G, Taranto P, Glitza I et al. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019; 11: 1–16.
51. Rutkowski P, Wysoczki PJ, Nasirowska-Guttmejer A et al. Cutaneous me lanoma. Oncol Clin Pract. 2019; doi: 10.5603/OCP.2018.0055.
52. Sarkissian S, Rearick C, Davar D. Targeted therapy and immunotherapy in the treatment of metastatic cutaneous melanoma hospital physician. Hematology/Oncology. 2017.